Figure 2 — The efficacy of adding hyperthermia to the treatment of advanced NSCLC patients based on the states of EGFR

Research Paper|Volume 14, Issue 12|pp. 5223–5232

The efficacy of adding hyperthermia to the treatment of advanced NSCLC patients based on the states of EGFR

100%

Figure 2.The subgroups analysis of non-EGFR mutation between two groups. (A) 1-year OS rates of non-EGFR mutation between two groups (P<0.05). (B) 1-year PFS_first rates of non-EGFR mutation between two groups (P<0.01).